Chinese expert consensus on drug therapy and pharmaceutical care of atopic dermatitis
With the highest global disease burden,atopic dermatitis(AD)is a chronic inflammatory skin disease requiring positive treatment and long-term management.In the past,topical corticosteroids(TCS),topical calcineurin inhibitors(TCI)and systemic immunosuppressants acted as major treatments for AD.Due to patient concerns of adverse reactions of TCS and tra-ditional immunosuppressants,as well as uneven medical levels among different regions,clinical therapy of AD,especially sys-temic therapy of moderate-to-severe AD,often faces the problems of delayed initiation and poor patient compliance.Recently tar geted drugs such as biologics and Janus kinase(JAK)inhibitors have been successively approved and systemic therapy for AD has gradually improved.However,due to relatively limited clinical application experiences of these drugs,drug selection,drug tim-ing,tapering and withdrawing,adverse reaction management and other issues have brought new challenges to clinical therapy.With the introduction of the concept of"treat-to-target",AD therapy has emphasizes primary patient needs,guidance of therapy goal and individualized management.Therefore therapeutic drug dosing and patient compliance management have become impor-tant factors affecting the"treat-to-target".And pharmaceutical care plays a growingly prominent role in the management of AD therapeutic drugs.This consensus was intended to standardize drug use in AD management,summarize key points of pharmaceuti-cal care,ensure drug safety and improve patient medication compliance,thereby improving the therapy outcomes and promoting the quality of AD therapy management in China.
NETL
NSTL
万方数据
